Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology
Authors:
- M. De LaurentiisMLM. De Laurentiis
- G. CancelloGCG. Cancello
- L. ZinnoLZL. Zinno
- E. MontagnaEME. Montagna
- L. MalorniL. Malorni
- A. EspositoAEA. Esposito
- R. PennacchioRPR. Pennacchio
- L. SilvestroLSL. Silvestro
- M. GiulianoMGM. Giuliano
- A. GiordanoA. Giordano
- F. CaputoFCF. Caputo
- A. AccursoAAA. Accurso
Open Access
- 1 May 2005
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 16 (suppl_4) , iv7-iv13
Abstract
Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanised recombinant monoclonal antibody that recognizes the extracellular domain of HER2 trans-membrane protein, is among the first target-specific drugs that have been licensed for clinical use and its development represents a model of integration of new agents with classical treatment strategies. In preclinical models, trastuzumab has demonstrated a marked antiproliferative effect and a synergistic action with several chemotherapeutic agents. Monotherapy trials indicate that trastuzumab is active as a single agent in HER2 positive patients, is well tolerated, and is associated with preservation of quality of life (QoL). Furthermore, as first line therapy for metastatic breast cancer overexpressing HER2 receptor, the addition of trastuzumab to taxane-based chemotherapy significantly increased rate of objective response, time to disease progression and survival when compared with chemotherapy alone. Trastuzumab has shown important activity when used with many chemotherapeutic agents such as platinum salts, gemcitabine, vinorelbine and capecitabine and liposomal anthracyclines. Various trials are now ongoing to optimize the use of trastuzumab and to investigate its role in the adjuvant and in the neo-adjuvant setting.Keywords
This publication has 28 references indexed in Scilit:
- Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancerEuropean Journal of Cancer, 2004
- Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease ProgressionJournal of Clinical Oncology, 2004
- Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization–Positive Metastatic Breast Cancer: A Multi-Institutional Phase II TrialJournal of Clinical Oncology, 2004
- A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast CancerOncology, 2004
- Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast CancerThe Oncologist, 2002
- Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogeneEuropean Journal of Cancer, 2001
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 1999
- The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for TherapyStem Cells, 1998
- Receptor blockade with monoclomal antibodies as anti-cancer therapyPharmacology & Therapeutics, 1994
- Amplification of a Novel v- erb B-Related Gene in a Human Mammary CarcinomaScience, 1985